Ripasudil

SENSORY ORGANS

Key facts

Ripasudil is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2014. DrugCentral lists 18 molecular targets, including ROCK2, ROCK1 and PKN2. Recorded indications include Glaucoma and Ocular hypertension.

• Molecular targets: ROCK2, ROCK1, PKN2 and PKN1 (18 listed in DrugCentral).
• Indications: Glaucoma and Ocular hypertension.
• ATC code: S01EA55 (Sympathomimetics in glaucoma therapy).
• Molecular formula: C15H18FN3O2S; molecular weight 323.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Glaucoma
• Ocular hypertension

Mechanism & targets

Molecular targets (18)

Target	Gene	Action	Activity
Rho-associated protein kinase 2	ROCK2	inhibitor	IC50 7.72
Rho-associated protein kinase 1	ROCK1	inhibitor	IC50 7.29
Serine/threonine-protein kinase N2	PKN2	unknown	Kd 6.54
Serine/threonine-protein kinase N1	PKN1	unknown	Kd 6.38
Aurora kinase B	AURKB	unknown	Kd 5.94
5'-AMP-activated protein kinase subunit gamma-1	PRKAG1	unknown	Kd 5.74
cAMP-dependent protein kinase catalytic subunit alpha	PRKACA	inhibitor	IC50 5.68
Protein kinase C delta type	PRKCD	unknown	Kd 5.61
Dual specificity mitogen-activated protein kinase kinase 3	MAP2K3	unknown	Kd 5.51
5'-AMP-activated protein kinase catalytic subunit alpha-1	PRKAA1	unknown	Kd 5.49
Mitogen-activated protein kinase kinase kinase kinase 3	MAP4K3	unknown	Kd 5.49
Ribosyldihydronicotinamide dehydrogenase [quinone]	NQO2	unknown	Kd 5.43
Serine/threonine-protein kinase D2	PRKD2	unknown	Kd 5.43
Serine/threonine-protein kinase MARK2	MARK2	unknown	Kd 5.22
Serine/threonine-protein kinase PLK4	PLK4	unknown	Kd 5.09
Serine/threonine-protein kinase TAO3	TAOK3	unknown	Kd 4.93
Cyclin-dependent kinase 9	CDK9	unknown	Kd 4.88
MAP/microtubule affinity-regulating kinase 3	MARK3	unknown	Kd 4.24

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2014-09-26	PMDA	—	Kowa Company, Ltd

ATC classification

ATC code	Therapeutic hierarchy
S01EA55	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Sympathomimetics in glaucoma therapy
S01EX07	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Other antiglaucoma preparations

Chemical structure

• Molecular formula: C₁₅H₁₈FN₃O₂S
• Molecular weight: 323.39 g/mol
• CAS number: —
• InChIKey: QSKQVZWVLOIIEV-NSHDSACASA-N
• PubChem CID: 9863672

C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ripasudil used for?

DrugCentral lists the following indications for Ripasudil: Glaucoma and Ocular hypertension.

How does Ripasudil work?

Its molecular targets in DrugCentral include ROCK2 (inhibitor), ROCK1 (inhibitor), PKN2 and PKN1.

When was Ripasudil first approved?

Ripasudil was first approved by the PMDA in 2014.

What is the chemical formula of Ripasudil?

Ripasudil has the molecular formula C15H18FN3O2S and a molecular weight of 323.39 g/mol.

Sources

• DrugCentral drug card 4938 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3426621 — compound record and bioactivity
• PubChem CID 9863672 — chemical identifiers
• DrugBank DB13165 — drug record
• FDA UNII 11978226XX — substance identity
• UniProt O75116 (ROCK2) — target protein
• UniProt Q13464 (ROCK1) — target protein
• UniProt Q16513 (PKN2) — target protein
• UniProt Q16512 (PKN1) — target protein
• UniProt Q96GD4 (AURKB) — target protein
• UniProt P54619 (PRKAG1) — target protein

How this page is built: methodology · editorial policy & corrections.